ORIC Pharmaceuticals Share Price Today: Live Updates & Key Insights

ORIC Pharmaceuticals share price today is $11.16, up 0.54%. The stock opened at $10.92 against the previous close of $11.1, with an intraday high of $11.365 and low of $10.77.

ORIC Pharmaceuticals Share Price Chart

ORIC Pharmaceuticals

us-stock
To Invest in {{usstockname}}
us-stock

ORIC Pharmaceuticals Share Price Performance

$11.16 0.0054(0.54%) ORIC at 23 Mar 2026 02:37 PM Biotechnology
Lowest Today 10.77
Highest Today 11.365
Today’s Open 10.92
Prev. Close 11.1
52 Week High 14.93
52 Week Low 3.90
Day’s Range: Low 10.77 High 11.365
52-Week Range: Low 3.90 High 14.93
1 day return -
1 Week return -8.44
1 month return -4.48
3 month return +33.05
6 month return +3.33
1 year return +51.76
3 year return +140.21
5 year return -56.48
10 year return -

ORIC Pharmaceuticals Institutional Holdings

Nextech Invest, Ltd. 6.39

EcoR1 Capital, LLC 6.01

Viking Global Investors LP 5.87

VR Adviser, LLC 5.07

Pfizer Inc 4.80

BlackRock Inc 4.71

Vanguard Group Inc 4.06

SR ONE CAPITAL MANAGEMENT, LP 4.03

Alkeon Capital Management, LLC 4.02

NEA Management Company, LLC 3.68

Orbimed Advisors, LLC 3.25

Column Group LLC 3.16

State Street® SPDR® S&P® Biotech ETF 2.63

T. Rowe Price Associates, Inc. 2.56

Point72 Asset Management, L.P. 2.34

FMR Inc 2.21

JPMorgan Chase & Co 2.19

Vanguard Total Stock Mkt Idx Inv 2.19

Citadel Advisors Llc 2.17

State Street Corp 2.15

Paradigm Biocapital Advisors LP 2.14

ACAP Strategic A 1.99

First Turn Management LLC 1.93

T. Rowe Price Health Sciences 1.50

iShares Russell 2000 ETF 1.43

Fidelity Growth Compy Commingled Pl S 1.18

Biotech Growth Ord 0.87

Eventide Healthcare & Life Sciences I 0.85

T. Rowe Price New Horizons 0.77

Vanguard Institutional Extnd Mkt Idx Tr 0.75

Franklin Biotechnology Discv A(acc)USD 0.67

US Small-Cap Growth II Equity Comp 0.66

Fidelity Growth Company Fund 0.64

T. Rowe Price Integrated US Sm Gr Eq 0.62

Fidelity Small Cap Index 0.58

T. Rowe Price Integrated US SmCapGrEq 0.55

Franklin Biotechnology Discovery A 0.47

Polar Capital Biotech S Inc 0.42

Royce Small-Cap Trust 0.39

Royce Micro-Cap Trust 0.37

ORIC Pharmaceuticals Market Status

Strong Buy: 10

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

ORIC Pharmaceuticals Fundamentals

Market Cap 1250.00 M

PB Ratio 3.2259

PE Ratio 0.0

Enterprise Value 965.12 M

Total Assets 411.00 M

Volume 3695607

ORIC Pharmaceuticals Company Financials

Annual Revenue FY25:null 0.0M, FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M

Annual Profit FY25:-1220000 -1.2M, FY24:null 0.0M, FY23:-1032000 -1.0M, FY22:null 0.0M, FY21:null 0.0M

Annual Net worth FY25:-129468000 -129.5M, FY24:-127847000 -127.8M, FY23:-100697000 -100.7M, FY22:-91477000 -91.5M, FY21:-77677000 -77.7M

Quarterly Revenue Q4/2025:null 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:0 0.0M

Quarterly Profit Q4/2025:-320000 -0.3M, Q3/2025:null 0.0M, Q2/2025:-310000 -0.3M, Q1/2025:-302000 -0.3M, Q4/2024:null 0.0M

Quarterly Net worth Q4/2025:-30505000 -30.5M, Q3/2025:-32587000 -32.6M, Q2/2025:-36355000 -36.4M, Q1/2025:-30021000 -30.0M, Q4/2024:-36307000 -36.3M

About ORIC Pharmaceuticals & investment objective

Company Information ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 104

Industry Biotechnology

CEO Dr. Jacob M. Chacko M.B.A., M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

ORIC Pharmaceuticals FAQs

What is the share price of ORIC Pharmaceuticals today?

The current share price of ORIC Pharmaceuticals is $11.16.

Can I buy ORIC Pharmaceuticals shares in India?

Yes, Indian investors can buy ORIC Pharmaceuticals shares by opening an international trading and demat account with Motilal Oswal.

How to buy ORIC Pharmaceuticals shares in India?

You can easily invest in ORIC Pharmaceuticals shares from India by:

Can I buy fractional shares of ORIC Pharmaceuticals?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of ORIC Pharmaceuticals?

ORIC Pharmaceuticals has a market cap of $1250.00 M.

In which sector does ORIC Pharmaceuticals belong?

ORIC Pharmaceuticals operates in the Biotechnology sector.

What documents are required to invest in ORIC Pharmaceuticals stocks?

To invest, you typically need:

What is the PE and PB ratio of ORIC Pharmaceuticals?

The PE ratio of ORIC Pharmaceuticals is N/A and the PB ratio is 3.23.